Free Trial

Bausch Health Companies Q3 2024 Earnings Report

Bausch Health Companies logo
$7.74 +0.06 (+0.78%)
(As of 12:16 PM ET)

Bausch Health Companies EPS Results

Actual EPS
$1.12
Consensus EPS
$1.02
Beat/Miss
Beat by +$0.10
One Year Ago EPS
$1.03

Bausch Health Companies Revenue Results

Actual Revenue
$2.51 billion
Expected Revenue
$2.42 billion
Beat/Miss
Beat by +$88.62 million
YoY Revenue Growth
+12.20%

Bausch Health Companies Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Healthcare Takes A Big Step Forward With The Help of A.I. (Ad)

To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

Bausch Health Companies Earnings Headlines

Bausch Health says Bausch + Lomb sale exploration process ‘ongoing’
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
See More Bausch Health Companies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch Health Companies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch Health Companies and other key companies, straight to your email.

About Bausch Health Companies

Bausch Health Companies (NYSE:BHC) operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

View Bausch Health Companies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings